Completed PHASE4 INTERVENTIONAL 2-arm NCT00149227

Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study)

Add-on Effects of Valsartan on Morbi- Mortality in High Risk Hypertension

Sponsor: Kyoto Prefectural University of Medicine

Conditions Congestive Heart Failure Hypertension Ischemic Heart Disease Stroke

Updated 9 times since 2017 Last updated: Dec 9, 2012 Started: Jan 31, 2004 Primary completion: Jan 31, 2009 Completion: Jan 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Congestive Heart Failure and Hypertension, this trial is completed. The trial is conducted by Kyoto Prefectural University of Medicine and has accumulated 9 data snapshots since 2004. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

9 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE4
Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4

▶ Show 4 earlier versions

Dec 2021 — Dec 2022 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jan 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kyoto Prefectural University of Medicine

Data source: Kyoto Prefectural University of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kyoto, Japan